
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems Inc. has demonstrated strong financial performance, with cardiovascular sales reaching $366 million, reflecting a robust growth rate of 12.9%, attributed to advancements in Peripheral and Cardiac Intervention as well as Custom Procedural Solutions. The company's gross margin increased by 270 basis points to a historic high of 53.6%, driven by effective pricing strategies and an advantageous product mix, while the operating margin improved to 19.7%, marking a 50 basis point increase year-over-year. Furthermore, organic revenue growth expanded to 7.8%, indicating sustained operational progress and financial resilience within the medical equipment sector.
Bears say
Merit Medical Systems Inc faces several financial challenges that contribute to a negative outlook, including risks of worse-than-expected margin performance and free cash flow, coupled with slower growth projections, particularly in China. The company's recent revenue growth of only 5% or lower from recent acquisitions and unsuccessful new product launches indicates potential operating margin contraction and earnings below consensus estimates. Additionally, despite a reported 3Q revenue increase to $384.2 million, the disappointing news regarding the lack of transitional pass-through payments and downward adjustments in earnings per share guidance further undermine investor confidence in the firm’s financial stability.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares